Trial Profile
Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 May 2021
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Biliary cancer
- Focus Therapeutic Use
- 17 May 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 17 May 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 15 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.